



Workshop Highlights and Recommendations
ABC 4 featured four concurrent workshops focusing on areas of con-
cern in agricultural biotechnology: Animal Well-Being, Links of Animal 
Biotechnology to Human Health, Meat and Animal Product Safety and Regu-
latory Issues. In the workshops, participants were asked to define and 
prioritize national issues, reach consensus where possible, and to develop 
recommendations. The diversity of participants helped to insure that a wide 
variety of issues were raised; at the same time, diverse values and goals often 
made consensus difficult. Consequently, workshops were also charged with 
identifying areas of disagreement both of fact and perception. The following 
highlights are from reports prepared by workshop co-chairs and reviewed by 
all participants in those workshops. Any inaccuracies are the result of editing 
and not the responsibility of the original writers. Full versions of the work-
shop reports and summaries, as well as background presentations, can be 
found in Part II starting on page 23.
he workshop began with a wide-ranging discussion about the concept
of well-being. Participants decided that the discussions should be lim-
ited to the well-being of animals involved in biotechnology: farm animals 
and experimental animals. Many felt that new technologies create new prob-
lems and raised new questions.
Individual participants listed 15 questions about biotechnology and ani-
mal well-being. It was observed that the emergence of biotechnology coin-
cides with greater concerns about animals, increasingly cognitive views of 
animals, increased distance from agricultural and draft uses of animals, and 
urbanization and romanticization of animals. Technology is colliding with 
changing morality. Genetic engineering feeds into these concerns because of the 
general concern that the manipulation of genes could lead to unnatural beings.
By this point in the discussion the participants were quite polarized. To 
move the discussion forward it was suggested that some of the fundamental
Biotechnology and Animal Well-Being
concerns might be identified. Among the 16 listed were: whether it is ever ac-
ceptable to utilize animals for human use, whether animal biotechnology 
poses unique questions about animal well-being and whether biotechnology is 
qualitatively or quantitatively different from what has come before.
Following an intense discussion on the concerns, individual participants 
identified some possible harms and benefits to animal well-being that arise 
in the context of biotechnology. A highly unrepresentative straw poll was then 
done in order to see which of these possible harms and benefits the partici-
pants most wanted to discuss. The four possible harms (1. diverting 
resources away from improving traditional husbandry practices; 2. loss of 
genetic diversity; 3. proliferation of genetically defective animals who suffer 
disease as models; and 4. thinking of domestic animals as human artifacts), 
and the four possible benefits (1. removal of genetic defects from animal 
populations more rapidly; 2. better understanding of animal well-being;
3. permitting increased disease resistance; and 4. more efficient production 
leading to the use of fewer animals) receiving the most support, along with 
the possibility that animal biotechnology may lead to healthier products for both 
humans and animals, formed the basis of much of the remaining discussion.
CONSENSUS STATEMENTS
Weighing the broad spectrum of issues related to biotechnology and animal 
well-being, participants were able to reach agreement on four consensus 
statements:
1. Biotechnology may contribute to animal well-being, but it is not the 
only approach to improving animal well-being.
2. There should be responsible, systematic investigation of the benefits 
and harms to animals that may be associated with biotechnology.
3. It is acceptable under some conditions to use animals for human use.
4. Animal biotechnology has the potential to contribute to the “three Rs” 
in animal experimentation: reduction, refinement and replacement.
RECOMMENDATIONS
1. With respect to animal well-being, criteria should be developed for re-
sponsible research and application of specific biotechnologies in animals. The 
full spectrum of opinion should be represented in the development of these cri-
teria. These criteria should be periodically reconsidered in the light of 
changing circumstances.
2. The benefits and harms noted should be taken into account in develop-
ing these criteria.
3. Animal biotechnology should not be used in ways that impose great 
costs in animal well-being while achieving only minor human or animal ben-
efits. When there is the likelihood that a procedure will cause great suffering 
to animals, alternatives should be sought.
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Links of Animal Biotechnology to Human Health
As a result of the advances made in molecular biology over the last decade, the fields of animal agriculture and human medicine have come to share 
a wide range of techniques and models. These profound changes in the re-
search process have raised a series of issues with respect to the use of both 
farm and traditional laboratory animals in research. The discussions in this 
workshop focused on these issues.
HUMAN HEALTH CONSIDERATIONS DRIVING AGRICULTURAL 
RESEARCH
In recent years, public concern about food safety and nutrition has played an 
increasing role in animal agricultural research. The public is also concerned 
about the disclosure of the contents of food and food products as well as 
about broader marketing issues (e.g., product claims).
In addition, new biotechnologies blur the lines between nutrition and 
pharmacy, making possible the creation of what have been variously called 
“nutraceuticals” and “pharmafoods.” These products, often of animal origin, 
serve a combination of nutritive and therapeutic goals. They raise complex 
issues of regulation, food safety and consumer education.
ETHICAL USE OF ANIMALS
Some argue that the use of animals as food or in research is itself unethical. 
Others argue that humane treatment of animals is the major concern. The 
workshop participants agreed that it was not clear just what is ethical. More-
over, they were concerned with methods used to accommodate the wide 
range of views on the subject found in our diverse society. They also ques-
tioned whether current guidelines on the use of animals in research, often 
written before the advent of the new technologies, are adequate morally.
ANIMALS FOR BIOLOGICS AND THERAPEUTICS
The use of animals for the production of vaccines and therapeutics has a long 
history. Workshop members indicated that the widespread use of animals as 
living “bioreactors” to produce chemicals of value to humans differed from 
other uses of animals, (e.g., in food and fiber production). They expressed 
concern as to what, if any, ethical implications were associated with it. More-
over, the use of animals as bioreactors raises some practical questions. For 
example, there is the problem of what to do with the carcasses of these ani-
mals. Should they be allowed to enter the food chain?
Animal bioreactors also pose problems of containment, welfare and 
management, raising the question of whether it would be more desirable to 
have certain species earmarked for this purpose and not used for food. This, 
in turn, raised the issue of whether whole animals or cell cultures should be 
used for screening of therapeutic products.
Workshop Recommendations
SOCIETAL CONTEXT OF SCIENCE SHARED BY AGRICULTURE AND 
MEDICINE
Research rarely takes place outside a larger social context. That context pro-
vides both the limits and opportunities for research. A central issue in this 
workshop was how (or whether) to integrate private and public research at 
the agriculture-medicine interface. Another key issue was the distributive as-
pects of this type of research.
The group also acknowledged that new linkages between the medical 
and agricultural sciences will be influenced by the current state of food, agri-
cultural and medical policy. At the same time, the discoveries and inventions 
stemming from this research will have a considerable impact on food, agri-
cultural, and medical policies. In addition, workshop participants wondered 
whether the current institutional structures (especially at universities) were 
adequate for the new linkages between agriculture and medicine.
Finally, there was a general consensus that greater public participation 
in the decision-making process was both necessary and desirable.
RECOMMENDATIONS
1. Stronger links need to be developed between agricultural and medical 
research relating to biotechnology. Among mechanisms to do so are centers, in-
centives for joint programs, funding, etc. This will require further integration 
and institutionalization of joint agricultural and medical programs. Such link-
ages will need to include an examination of the ethical, economic, social, insti-
tutional, and legal ramifications of these changes.
2. More resources from molecular biology should be devoted to genome 
and other research in an attempt to ultimately spare animals from direct use 
in research. It should be thereby possible to shift largely from whole animal to 
organ, tissue or cellular systems.
3. Explore the moral implications of the use of animals in medical and ag-
ricultural research. Issues in the area are currently inadequately examined, and 
thus, there is not yet an adequate moral framework for making decisions about 
this type of research.
4. Provide for education of and dialogue among all the participants in the 
debate.
5. Improve the agenda-setting process that insures that resources are 
properly allocated and that all interested parties are involved in the allocation 
process.
6. Improve the guidelines to aid in determining appropriate circum-
stances for patenting animals, tissues, and cell lines.
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Meat and Animal Product Safety
Workshop participants identified some potential safety problems fordiscussion. These included unanswered questions about bovine soma-
totropin (BST), allergenicity and questions about a number of products for 
which there are, as yet, no data bases. Participants also discussed the promise 
for new biotechnologies to produce diagnostic tools for food safety testing of 
animal products.
Finding common ground was more difficult and frustrating once the 
group moved past the fairly narrow, but controllable technical hazards to the 
myriad of intellectual and social elements that people bring to a decision 
about the safety of any entity, food included. At this point, participants 
stepped back to list the major concern of each of the participants about the 
safety of biotechnologically produced meat and animal products. The items 
fell into four different areas. Small groups were formed to discuss these issues 
and bring recommendations back to the total workshop group for discussion.
THE SAFETY OF TRANSGENIC ANIMALS AND ANIMALS ADMINISTERED 
RECOMBINANT DNA PRODUCTS
In the area of use of transgenic animals to produce pharmaceutical agents for 
use by humans, the major safety concern was that these “pharm” animals may 
enter the human food supply, but before they do, their safety must be assured.
1. All workshop participants agreed to the need for a data base on the nu-
trient composition and levels of relevant hormones and residues in these 
animals to reassure scientists and the public that there are no detectable dif-
ferences from levels of these substances in traditional animal products. There 
was not consensus in the group as to how extensive the data base would be 
and what it would contain.
In the area of animals administered recombinant DNA products: 1. hor-
mones; 2. vaccines; and 3. direct-fed microbials; there was consensus that the 
regulations under the National Environmental Protection Act (NEPA) and 
the testing protocols for vaccines were probably adequate. FDA has the au-
thority to regulate direct-fed microbials, but the group felt it has not been 
doing so.
2. FDA should investigate direct-fed microbials more carefully in the fu-
ture when applications for recombinant products are received.
Another concern expressed was about long-term consequences of breed-
ing transgenic animals. The concern here is the unknown potential for 
unexpressed genes to cause other changes in animals that may not be ex-
pressed for several generations.
3. The final recommendation in this area speaks to the need for remain-
ing aware of the possibility of cloning defects in embryo transfer and cloning 
experiments.
Workshop Recommendations
BIOTECHNOLOGICAL TOOLS TO ENHANCE FOOD SAFETY 
AND QUALITY
4. Recognizing that animal products are the major source of microbial 
contamination in the food supply, the use o f  D N A  probe assays and immu-
noassays for the detection of pathogens is to be strongly encouraged.
Biotechnology is the most promising source of tools that can yield rapid, 
sensitive, specific and cost-effective diagnostic tests for the presence of mi-
crobiological pathogens, antigens, toxins and other compounds of interest to 
improve food safety. New diagnostic capabilities can also be used to detect 
adulterated foods and as a screening method for allergens in the food supply. 
The group also discussed how genetic markers offer the potential to improve 
the healthfulness and safety of the food supply.
5. Research and application of these tools should move ahead rapidly. 
They endorse continued research on the use of the genetic makers techniques.
DEFINING FOOD SAFETY
Some participants argued the present definition of “safe,” relative to foods, is 
too narrow, ignoring quality issues as well as the fact that food safety is a so-
cial construct. They felt that social, economic and political issues should be 
evaluated concurrently with the evaluation of efficacy and human and ani-
mal safety. Others disagreed with all of these ideas and argued for main-
taining the present system of relying solely on technical data for safety deci-
sions. The latter participants did recognize that social, economic and polit-
ical issues should be discussed, but there was no agreement about whether 
the mechanism should be separate from, or integral to, the present system.
6. The larger issue here is how to define food safety.
COMMUNICATING WITH THE PUBLIC
This section of the report and recommendations are premised on a consensus 
agreement that the public has a stake in maintaining public institutions pro-
vided they are responsive to public needs. Many (but not all) scientists have 
perceptions and biases that are quite different from the various perceptions 
and biases of public groups which makes it difficult for scientists to be good 
communicators. There is also the serious problem of lack of support for these 
activities in the reward structures of institutions and of an imbalance in 
funding going to high technology research versus research in policy and com-
munications. These were all considered in the following set of recommen-
dations which were endorsed by all workshop participants.
7. There is a body of knowledge about communications that scientists 
should use to improve the dialogue with the public.
8. Regional research projects should be promoted and funded, and the 
National Research Initiative should be encouraged to put more funding into 
its policy and marketing line item to promote public understanding of agricul-
tural biotechnology.
Animal Biotechnology: Opportunities & Challenges
9. Interdisciplinary work between the biological and social sciences 
should be promoted and recognized as critical if serious progress in this area is 
expected.
10. In all grant proposals, the technical significance and relevance of re-
search should be communicated in terms the general public (or anyone outside 
the particular discipline) can understand.
11. Continuing education programs should be developed for scientists to 
teach them how to more effectively facilitate two-way communication be-
tween scientists and the general public.
12. The public, starting at the elementary school level, would be well 
served by educational programs on the social, moral, economic, political and 
scientific issues surrounding biotechnology.
In order to accomplish any wide-ranging change in faculty behavior in 
these areas the group suggested that it will be necessary to re-envision the 
mission of the land-grant colleges to serve all their publics and recognize that the 
responsibility for this is shared by all institutions of higher education. This will 
change the weight given to public service or extension activities in promotion de-
cisions and bring this area into better balance with research and teaching.
Regulatory Issues
The charge to the workshop participants was to identify and examine issues arising in regulatory treatment of animal biotechnology. Free-ranging dis-
cussion among individuals with different perspectives followed. While 
consensus was not sought nor achieved on the specific issues identified, these 
issues were deemed worthy of consideration by one, some, or many of the 
members of the group, and as such help to illustrate the range of concerns in 
the regulatory arena. Common themes of agreement did emerge and these 
were captured in the form of four issue statements or recommendations at 
the end.
The following issues and gaps have been identified in the regulatory process: 
—At the research stage, there are no mandated guidelines/regulations 
for industrial research of animal biotechnology.
—In field testing, there are no regulations for release of fish, wildlife, in-
sects or pets; for micro-organisms in livestock feeds or for zoonotic pathogens 
of animals and humans. Also there is no mechanism to deregulate similar ge-
netically modified organisms that have been proven to be safe based upon 
previous case studies;
—Implementation of the ABRAC developed guidelines should govern 
agricultural research in the area of field testing;
—There is an inability to gain access to some information on health and 
safety of products because of “confidential business information” designation.
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—In the food safety area there are gaps that are currently not covered by 
any regulations including disposition of transgenic animals and whether fish, 
seafood and wildlife should be included.
—In efficacy testing, the issue of whether transgenic animals used as 
pharmacoreactors should receive special attention from FDA was raised.
Recognizing there should be representation of broad interest, the public’s 
role in regulatory debate was discussed. Possible mechanisms identified for 
improved public access included: 1. legislation regarding public participa-
tion in regulating decisions across the board; 2. publication beyond the 
Federal Register; 3. improved representation in decision-making processes;
4. open forums; 5. research on opening up scientific decision-making 
process; and 6. rebuilding public trust and regulatory transparency.
Other issues considered were the role of states and industry in the de-
bates, public education, and communication. Consideration was given by the 
group to the level of information available for consumer choice.
Workshop participants also considered technically based regulations vs 
social/ethical/economic impact considerations. They noted that regulations 
can impact not only in the U.S., but also on international trade, as well as 
trade relationships with Third World countries.
RECOMMENDATIONS
1. The regulatory gaps delineated deserve serious investigation. NABC 
may wish to establish a committee or other mechanism to assist this investigation.
2. A more acceptable policy-making process for rules of broad applicabil-
ity would be clearly understood or known (not ad hoc), transparent, and 
participatory. The group viewed the process by the Council on Competitiveness 
in the Office of the Vice President, leading to the May 26, 1992 FDA food safety 
decision, as falling short of the goals for an acceptable process. (Editor’s note: At 
the final plenary session, a recommendation was made by those present (no op-
position was voiced) that NABC respond urging future processes of policy 
development be open and include all interested stakeholders. NABC sent letters 
to Vice President Dan Quayle and the heads of HHS, FDA, EPA and USDA.)
3. Social, economic and ethical questions need to be explored. What role 
do/should these issues have in research, development and approval processes for 
commercial use of new products? When should these factors be considered, rela-
tive to, but not necessarily as a part of, the regulatory process?
4. With broader representation, (such as food processors and consumer 
groups), NABC should conduct further exploration of the relationship be-
tween the government’s regulatory role, particularly the safety statutes and 
issues of choice, such as labeling provisions.
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